Muscle Protein Synthesis After Whole Egg vs. Egg White Consumption
| Status: | Completed |
|---|---|
| Conditions: | Orthopedic |
| Therapuetic Areas: | Orthopedics / Podiatry |
| Healthy: | No |
| Age Range: | 18 - 35 |
| Updated: | 5/3/2018 |
| Start Date: | July 2015 |
| End Date: | May 2017 |
The Consumption of Whole Eggs Versus Egg Whites to Stimulate Postprandial Muscle Protein Synthesis
In crossover trials, ten (N=10) young men (18-35 y) will receive stable isotope tracer
infusions and perform a single bout of resistance exercise. Immediately after resistance
exercise, participants will ingest stable isotope labeled whole eggs (18 g protein, 17 g fat)
or egg whites (18 g protein, 0 g fat) cooked in scrambled form. Repeated blood and muscle
biopsies will be collected to determine whole body amino acid kinetics, muscle amino acid
transporters, anabolic signaling and myofibrillar protein synthesis rates during the trials.
infusions and perform a single bout of resistance exercise. Immediately after resistance
exercise, participants will ingest stable isotope labeled whole eggs (18 g protein, 17 g fat)
or egg whites (18 g protein, 0 g fat) cooked in scrambled form. Repeated blood and muscle
biopsies will be collected to determine whole body amino acid kinetics, muscle amino acid
transporters, anabolic signaling and myofibrillar protein synthesis rates during the trials.
On both infusion trials, participants will report to the laboratory at 0700 h after an
overnight fast. Upon arrival to the lab, a baseline breath sample will be collected for
determination of 13CO2 enrichment by isotope ratio mass spectrometry. A Teflon catheter will
be inserted into an antecubital vein for baseline blood sample collection (t=-210 min) and
then participants will receive priming doses of NaH13CO2 (2.35 µmol·kg-1), L-[1-13C]leucine
(7.6 µmol·kg-1), and L-[ring-2H5]phenylalanine (2.0 µmol·kg-1). Subsequently, a continuous
intravenous infusion of L-[1-13C]leucine (0.10 µmol·kg-1·min-1) and L-[ring-2H5]phenylalanine
(0.05 µmol·kg-1·min-1) will be initiated (t=-210 min) and maintained over the infusion
trials. A second Teflon catheter willinserted into a heated dorsal hand vein for repeated
arterialized blood sampling and remained patent by a 0.9% saline drip. Breath samples and
arterialized blood samples and will be collected every 30 or 60 min during the
postabsorptive- and postprandial states. In the post-absorptive state of infusion trial 1,
muscle biopsies will be collected at t=-150 and -30 min of infusion to determine basal-state
myofibrillar protein synthesis rates, relative skeletal muscle amino acid transporter
content, and anabolic-related signaling. In the subsequent cross-over trial only 1 muscle
biopsy will be collected at t=-30 for Western blot analysis and postabsorptive myofibrillar
protein-bound tracer enrichment. After collection of the resting muscle biopsy at t=-30 for
both trials, the participants will perform resistance exercise that consists of 4 sets of 10
repetitions at 80% of 10-RM for both leg press and leg extension exercise.
Immediately after completion of the exercise bout, participants will consume 3 whole eggs or
an equivalent amount of protein from egg whites (t=0 min). Completion of the meal will mark
the start of the postprandial phase (t=0 min) and additional muscle biopsies will be
collected at t=120 and 300 min.
overnight fast. Upon arrival to the lab, a baseline breath sample will be collected for
determination of 13CO2 enrichment by isotope ratio mass spectrometry. A Teflon catheter will
be inserted into an antecubital vein for baseline blood sample collection (t=-210 min) and
then participants will receive priming doses of NaH13CO2 (2.35 µmol·kg-1), L-[1-13C]leucine
(7.6 µmol·kg-1), and L-[ring-2H5]phenylalanine (2.0 µmol·kg-1). Subsequently, a continuous
intravenous infusion of L-[1-13C]leucine (0.10 µmol·kg-1·min-1) and L-[ring-2H5]phenylalanine
(0.05 µmol·kg-1·min-1) will be initiated (t=-210 min) and maintained over the infusion
trials. A second Teflon catheter willinserted into a heated dorsal hand vein for repeated
arterialized blood sampling and remained patent by a 0.9% saline drip. Breath samples and
arterialized blood samples and will be collected every 30 or 60 min during the
postabsorptive- and postprandial states. In the post-absorptive state of infusion trial 1,
muscle biopsies will be collected at t=-150 and -30 min of infusion to determine basal-state
myofibrillar protein synthesis rates, relative skeletal muscle amino acid transporter
content, and anabolic-related signaling. In the subsequent cross-over trial only 1 muscle
biopsy will be collected at t=-30 for Western blot analysis and postabsorptive myofibrillar
protein-bound tracer enrichment. After collection of the resting muscle biopsy at t=-30 for
both trials, the participants will perform resistance exercise that consists of 4 sets of 10
repetitions at 80% of 10-RM for both leg press and leg extension exercise.
Immediately after completion of the exercise bout, participants will consume 3 whole eggs or
an equivalent amount of protein from egg whites (t=0 min). Completion of the meal will mark
the start of the postprandial phase (t=0 min) and additional muscle biopsies will be
collected at t=120 and 300 min.
Inclusion Criteria:
- Male
- Aged 18-35 years
- Healthy, active (self-reported to exercise 2 - 4 times per week)
- BMI > 18.5 and < 25 kg/m2
Exclusion Criteria:
- Smoking
- Known allergies to egg consumption
- Vegans
- Diagnosed GI tract diseases
- Arthritic conditions
- A history of neuromuscular problems
- Diagnosed cognitive impairments
- Recent (1 year) participation in amino acid tracer studies
- Predisposition to hypertrophic scarring or keloid formation
- Individuals on any medications known to affect protein metabolism (i.e.
corticosteroids, non-steroidal anti-inflammatories, or prescription strength acne
medications).
- High blood pressure (Systolic > 140 mm HG; Diastolic > 90 mm HG)
We found this trial at
1
site
Click here to add this to my saved trials
